Immutep
Open
$0.46
Prev. Close
$0.46
High
$0.46
Low
$0.46
Market Snapshot
$69.75M
-8.6
-1.02
$19.26M
31
The company is headquartered in Sydney, New South Wales.
emptyResult
The company is headquartered in Sydney, New South Wales.
Recently from Cashu
Immutep Under Legal Investigation After TACTI-004 Phase III Study Halted
Immutep Faces Legal Scrutiny After Phase III Study Termination Immutep Ltd. is currently under investigation by the Rosen Law Firm, a leading global entity specializing in investor rights, over allega…
Immutep's TACTI-004 Trial Marks Crucial Turning Point for Future Development and Market Viability
Immutep Faces Critical Juncture in TACTI-004 Phase 3 Trial Immutep Limited, a biopharmaceutical company focusing on immunotherapy for cancer treatment, currently stands at a pivotal point as it naviga…
Immutep's TACTI-004 Trial Update Sparks Investor Concerns Over Future Growth Prospects
Immutep's TACTI-004 Trial Update Raises Concerns Immutep Limited's recent update regarding its TACTI-004 Phase 3 trial brings significant attention to the challenges that biotech companies face during…
Immutep Advances Autoimmune Therapy with IMP761 Trial Update on LAG-3 Agonist
Immutep Advances in Autoimmune Disease Treatment with IMP761 Trial Update Immutep Limited (NASDAQ: IMMP) announces a significant update on its Phase I clinical trial for IMP761, a groundbreaking LAG-3…